- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| GALERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.11. | Galera Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 22.10. | Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million | 917 | GlobeNewswire (Europe) | Galera has entered into an Asset Purchase Agreement with Toronto-based Biossil for Galera's dismutase mimetics portfolio, including all avasopasem and rucosopasem formulations and indications. The... ► Artikel lesen | |
| 21.10. | Galera Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 03.09. | Galera Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.08. | Galera Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 31.12.24 | Galera Therapeutics completes acquisition of Nova Pharmaceuticals | 476 | GlobeNewswire (Europe) | Galera's development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer. Lead program is Phase... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,510 | +3,96 % | Evotec Aktie: Wichtige Marke hält - jetzt einsteigen? | Bei der Evotec Aktie hat sich seit Monaten eine trendentscheidende Unterstützungszone etabliert. Mehrfach ist der Aktienkurs des Hamburger Biotech-Konzerns an der Kernmarke bei 5,06/5,11 Euro nach oben... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 46,200 | +4,05 % | CRISPR Therapeutics AG: CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering | -Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in... ► Artikel lesen | |
| MAINZ BIOMED | 1,010 | +5,04 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed und OncoVanguard8 unterzeichnen Vereinbarung zur Einführung von ColoAlert in Südamerika | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed und OncoVanguard8 unterzeichnen Vereinbarung zur Einführung von ColoAlert in Südamerika
18.11.2025... ► Artikel lesen | |
| TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| GALAPAGOS NV | 26,820 | 0,00 % | Gilead wants us to 'rebuild': Why Galapagos isn't allowed to go extinct after turbulent year | ||
| CELLECTAR BIOSCIENCES | 3,050 | +5,17 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom's Macroglobulinemia in 2026 Following Advice and Guidance from Scientific... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,808 | +0,78 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update | - Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer - - Expects to... ► Artikel lesen | |
| NOVOCURE | 10,770 | -0,92 % | Novocure auf der Jefferies London Konferenz: Expansionsstrategie in der Krebstherapie | ||
| SENSEI BIOTHERAPEUTICS | 9,000 | +2,04 % | Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results | BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics... ► Artikel lesen | |
| CYTOKINETICS | 58,00 | -0,85 % | Cytokinetics, Incorporated: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | ||
| CYTOMX THERAPEUTICS | 3,602 | +4,41 % | CytomX Therapeutics stock holds Overweight rating at Cantor Fitzgerald | ||
| SPERO THERAPEUTICS | 1,958 | -5,18 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update | PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero... ► Artikel lesen | |
| EIGER BIOPHARMACEUTICALS | 5,840 | -100,00 % | Eiger Express Permian-to-Gulf Coast natural gas pipeline will proceed, partners say | ||
| MINERVA NEUROSCIENCES | 3,180 | -4,22 % | Minerva Neurosciences, Inc: Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors | BURLINGTON, Mass., Nov. 19, 2025(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment... ► Artikel lesen | |
| VANDA PHARMACEUTICALS | 4,220 | -0,94 % | Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting | Vanda's Tradipitant Study Success Positions it as Key Adjunct in $50B+ Global GLP-1 Agonist Market
WASHINGTON, Nov. 17, 2025 /PRNewswire/ -- Vanda Pharmaceuticals... ► Artikel lesen |
GALERA THERAPEUTICS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GALERA THERAPEUTICS INC finden Sie auf Wallstreet Online.